🇺🇸 FDA

Intelligence · Clinical Pipeline

R&D Pipeline Programs

ClinicalTrials.gov programs linked to pharma sponsors — phase, modality, and trial IDs for BD and competitive intelligence.

Programs indexed
18,156
Companies
1,062
Drugs tracked
3,385

Quick answer

NovaPharmaNews tracks 18,156 pharmaceutical R&D pipeline programs sourced from ClinicalTrials.gov, linked to sponsor companies. Each profile includes development phase, modality, trial status, NCT identifiers, and indication text — searchable for business development and competitive intelligence.

94 results for “Novo Nordisk A/S” Clear

  1. A research study to compare blood levels of cagrilintide after multiple doses of different versions of cagrilintide in adults with overweight or obesity

    Novo Nordisk A/S

    obesity

    phase 1 other active

    1 trial

  2. A research study to evaluate the effects of single doses of NNC0614-0001 in healthy adult volunteers, and participants with hereditary haemochromatosis type 1.

    Novo Nordisk A/S

    Hereditary haemochromatosis (HH) type 1

    phase 1 other active

    1 trial

  3. A research study to evaluate the safety of NNC1679-0001 when given to healthy participants and participants with T2DM

    Novo Nordisk A/S

    Healthy participants and participants with type 2 diabetes

    phase 1 other active

    1 trial

  4. A research study to look at how CagriSema influences food intake, appetite and emptying of the stomach in people with excess body weight

    Novo Nordisk A/S

    Obesity

    phase 1 other active

    1 trial

  5. A research study to look at the distribution and effects of coramitug on amyloid deposits in heart tissue using PET/CT imaging in people with ATTR amyloidosis

    Novo Nordisk A/S

    transthyretin amyloid amyloidosis cardiomyopathy (ATTR-CM)

    phase 1 other active

    1 trial

  6. A research study to see how NNC0487-0111 affects the body’s energy use after a weight loss in adults living with obesity, compared to a low-calorie diet or placebo

    Novo Nordisk A/S

    Obesity

    phase 1 other active

    1 trial

  7. A study investigating the safety, absorption, and elimination of NNC0705-0001, a new compound that could potentially be used in the treatment of cardiometabolic diseases caused by inflammation.

    Novo Nordisk A/S

    Cardiometabolic diseases with an inflammatory component

    phase 1 other active

    1 trial

  8. A study of how CagriSema works on appetite in people with excess body weight

    Novo Nordisk A/S

    Obesity

    phase 1 other active

    1 trial

  9. A study to see the effect of NNC0194-0499 alone or in combination with semaglutide on blood sugar control in people living with type 1 diabetes.

    Novo Nordisk A/S

    Diabetes mellitus type 1

    phase 1 other active

    1 trial

  10. A study to test how a new long-acting insulin works in the body of patients with type 2 diabetes during exercise and prolonged fasting.

    Novo Nordisk A/S

    Type 2 diabetes

    phase 1 other active

    1 trial

  11. A study to test how insulin NNC0471-0119 H works in the body in participants with type 1 diabetes when given by an insulin pump.

    Novo Nordisk A/S

    Diabetes mellitus type 1

    phase 1 other active

    1 trial

  12. A study to test how insulin NNC0471-0119 works in the body in participants with type 2 diabetes when given by an insulin pump.

    Novo Nordisk A/S

    Diabetes mellitus type 2

    phase 1 other active

    1 trial

  13. A study understanding how much CDR132L enters the bloodstream after injection under the skin compared to injection into a vein in healthy participants

    Novo Nordisk A/S

    Healthy volunteers, treatment for heart failure

    phase 1 other active

    1 trial

  14. Investigating how CagriSema, semaglutide and cagrilintide regulate insulin effects in the body of people with type 2 diabetes.

    Novo Nordisk A/S

    Type 2 diabetes

    phase 1 other active

    1 trial

  15. Investigating how NNC0487-0111 regulates insulin in adults with type 2 diabetes

    Novo Nordisk A/S

    Type 2 Diabetes

    phase 1 other active

    1 trial

  16. Investigation of Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Subcutaneous Injections of NNC0582-0001 in Healthy Adults

    Novo Nordisk A/S

    Healthy Volunteers

    phase 1 other active

    1 trial

  17. Investigation of pharmacokinetics, safety and tolerability of a single subcutaneous dose of NNC0487-0111 in participants with various degrees of renal impairment and normal renal function.

    Novo Nordisk A/S

    Obesity and Diabetes mellitus Typ 2

    phase 1 other active

    1 trial

  18. The Role of the Amylin Analogue Cagrilintide in Bone Metabolism

    Novo Nordisk A/S

    Female (aged between 50-70 years (both included)) with obesity (BMI ≥ 30.0 kg/m2) of post-menopausal state at screening (defined as minimum 12 months of amenorrhea and high levels of follicular stimulating hormone (FSH) ≥16 UI/L. In cases of uncertainty, confirmation of postmenopausal status requires low levels of anti-Müllerian hormone (AMH) and inhibin B).

    phase 1 other active

    1 trial

  19. Understanding the effect of CagriSema, cagrilintide, and semaglutide on muscle health

    Novo Nordisk A/S

    Obesity, CCI, CCI

    phase 1 other active

    1 trial

  20. Lantus 100 units/ml solution for injection in a cartridge, Lantus 100 units/ml solution for injection in a vial, Toujeo 300 units/ml DoubleStar, solution for injection in a pre-filled pen, Awiqli 700 units/mL solution for injection in pre-filled pen, Levemir FlexPen 100 units/ml solution for injection in pre-filled pen., Toujeo 300 units/ml DoubleStar, solution for injection in a pre-filled pen, Tresiba 200 units/mL FlexTouch solution for injection in pre-filled pen, Tresiba 100 units/mL FlexTouch solution

    Novo Nordisk A/S

    Type 2 diabetes

    approved small molecule active

    1 trial

  21. Wegovy 0.25 mg FlexTouch solution for injection in pre-filled pen, Wegovy 1 mg FlexTouch solution for injection in pre-filled pen, Wegovy 0.5 mg FlexTouch solution for injection in pre-filled pen, Wegovy 2.4 mg FlexTouch solution for injection in pre-filled pen, Wegovy 1.7 mg FlexTouch solution for injection in pre-filled pen

    Novo Nordisk A/S

    Obesity

    approved small molecule active

    1 trial

  22. cagrilintide, Placebo + Placebo, semaglutide, cagrilintide, cagrilintide semaglutide, semaglutide, semaglutide, semaglutide, cagrilintide semaglutide, semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide semaglutide, cagrilintide, cagrilintide

    Novo Nordisk A/S

    Obesity and T2D

    approved small molecule active

    1 trial

Frequently asked questions

What is the NovaPharmaNews pipeline directory?

It is a searchable index of 18,156 clinical development programs grouped by sponsor company, with phase (Phase 1–3), modality, trial status, and linked NCT IDs from ClinicalTrials.gov.

Where does pipeline data come from?

Program records are derived from ClinicalTrials.gov and linked to NovaPharmaNews company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment or partnering decisions. See our data sources page for attribution.

How do I find pipeline programs by company or phase?

Use the search box to match program name, indication, company name, or slug. Results are ordered with late-stage (Phase 3) programs first. Open any row to view the full program profile under its sponsor company.

Data attribution and licensing: Data sources